Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28490104 | 0.87 | KDM4E (0.53) | KDM4EKMT2ASLC6A4SLC6A3SLC6A2 | |
| SCHEMBL11472669 | 0.83 | SLC6A4 (0.50) | KDM4EKMT2ASLC6A4SLC6A3SLC6A2 | |
| SCHEMBL29816321 | 0.83 | SLC6A4 (0.50) | KDM4EKMT2ASLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5361306 | 0.81 | SLC6A4 (0.57) | KDM4EKMT2ASLC6A4SLC6A3SLC6A2 | |
| SCHEMBL2272581 | 0.79 | DRD2 (0.53) | KDM4EKMT2ASLC6A4SLC6A3SLC6A2 | |
| SCHEMBL42581 | 0.77 | OPRL1 (0.52) | OPRL1 | |
| SCHEMBL5371709 | 0.72 | KDM4E (0.54) | KDM4EKMT2AOPRL1 | |
| SCHEMBL11362121 | 0.71 | OPRM1 (0.44) | SLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL3639977 | 0.71 | OPRL1 (0.52) | SLC6A4SLC6A3SLC6A2OPRL1 | |
| SCHEMBL8323383 | 0.71 | KDM4E (0.50) | KDM4EKMT2ASLC6A4SLC6A3OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | KDM4E 610/4885KMT2A 765/4885SLC6A4 10/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | KDM4E 610/4885KMT2A 765/4885SLC6A4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.